MedTrace Logo

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

NCT06250205 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-09-19

No results posted yet for this study

Summary

A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Obicetrapib

oral administration

DRUG

Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)

oral administration

DRUG

Drospirenone / Ethinyl Estradiol (COC)

oral administration

Sponsors & Collaborators

  • Novum

    collaborator INDUSTRY

  • NewAmsterdam Pharma

    lead INDUSTRY

Principal Investigators

  • Kent A Swaine · Novum Pharmaceutical Research Services, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-05
Primary Completion
2024-04-25
Completion
2024-04-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06250205 on ClinicalTrials.gov